[go: up one dir, main page]

CN1395578A - 吡啶并[2,3－d]嘧啶－2,7－二胺激酶抑制剂 - Google Patents

吡啶并[2,3－d]嘧啶－2,7－二胺激酶抑制剂 Download PDF

Info

Publication number
CN1395578A
CN1395578A CN01804048A CN01804048A CN1395578A CN 1395578 A CN1395578 A CN 1395578A CN 01804048 A CN01804048 A CN 01804048A CN 01804048 A CN01804048 A CN 01804048A CN 1395578 A CN1395578 A CN 1395578A
Authority
CN
China
Prior art keywords
pyrido
pyrimidin
urea
piperazin
anilino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01804048A
Other languages
English (en)
Chinese (zh)
Inventor
R·J·布斯
E·M·杜布鲁辛
V·P·V·N·珠斯于拉
D·J·麦克纳玛拉
P·L·图古德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of CN1395578A publication Critical patent/CN1395578A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
CN01804048A 2000-01-25 2001-01-23 吡啶并[2,3－d]嘧啶－2,7－二胺激酶抑制剂 Pending CN1395578A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17826100P 2000-01-25 2000-01-25
US60/178,261 2000-01-25

Publications (1)

Publication Number Publication Date
CN1395578A true CN1395578A (zh) 2003-02-05

Family

ID=22651853

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01804048A Pending CN1395578A (zh) 2000-01-25 2001-01-23 吡啶并[2,3－d]嘧啶－2,7－二胺激酶抑制剂

Country Status (34)

Country Link
EP (1) EP1254137A1 (xx)
JP (1) JP4047010B2 (xx)
KR (1) KR20020065939A (xx)
CN (1) CN1395578A (xx)
AP (1) AP2002002586A0 (xx)
AR (1) AR030044A1 (xx)
AU (1) AU2542501A (xx)
BG (1) BG106850A (xx)
BR (1) BR0107751A (xx)
CA (1) CA2397961C (xx)
CO (1) CO5261549A1 (xx)
CR (1) CR6706A (xx)
CZ (1) CZ20022475A3 (xx)
DZ (1) DZ3266A1 (xx)
EA (1) EA200200643A1 (xx)
EE (1) EE200200405A (xx)
GT (1) GT200100016A (xx)
HN (1) HN2001000013A (xx)
HU (1) HUP0204141A3 (xx)
IL (1) IL150545A0 (xx)
IS (1) IS6443A (xx)
MA (1) MA26868A1 (xx)
MX (1) MXPA02007221A (xx)
NO (1) NO20023527L (xx)
OA (1) OA12161A (xx)
PA (1) PA8510701A1 (xx)
PE (1) PE20011066A1 (xx)
PL (1) PL356802A1 (xx)
SK (1) SK10632002A3 (xx)
SV (1) SV2002000294A (xx)
TN (1) TNSN01014A1 (xx)
WO (1) WO2001055147A1 (xx)
YU (1) YU50402A (xx)
ZA (1) ZA200205879B (xx)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
CN1847229B (zh) 2000-10-23 2011-05-04 史密丝克莱恩比彻姆公司 2，4，8-三取代-8H-吡啶并[2，3-d]嘧啶-7-酮化合物
PE20030008A1 (es) * 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
EP1499320B1 (en) 2002-04-19 2007-08-22 Smithkline Beecham Corporation Novel compounds
US7504410B2 (en) * 2002-11-28 2009-03-17 Schering Aktiengesellschaft Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
US7157455B2 (en) * 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
TW200502236A (en) * 2003-03-28 2005-01-16 Hoffmann La Roche Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
FR2873118B1 (fr) 2004-07-15 2007-11-23 Sanofi Synthelabo Derives de pyrido-pyrimidine, leur application en therapeutique
EP1794160A1 (en) * 2004-09-21 2007-06-13 F.Hoffmann-La Roche Ag 6-(2-alkyl-phenyl) - pyrido[2,3-d] pyrimidines useful as proteine kinase inhibitors
EP1868612A4 (en) 2005-03-25 2010-03-24 Glaxo Group Ltd NOVEL CONNECTIONS
PE20061193A1 (es) 2005-03-25 2006-12-02 Glaxo Group Ltd DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38
UY29440A1 (es) 2005-03-25 2006-10-02 Glaxo Group Ltd Nuevos compuestos
CN101495475A (zh) 2005-03-25 2009-07-29 葛兰素集团有限公司 制备吡啶并[2,3-d]嘧啶-7-酮和3,4-二氢嘧啶并[4,5-d]嘧啶-2(1H)-酮衍生物的方法
FR2887882B1 (fr) 2005-07-01 2007-09-07 Sanofi Aventis Sa Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
CN101243081A (zh) * 2005-07-21 2008-08-13 霍夫曼-拉罗奇有限公司 作为PTP1B抑制剂的吡啶并[2,3-d]嘧啶-2,4-二胺化合物
BRPI0614804A2 (pt) * 2005-08-09 2011-04-12 Irm Llc compostos e composições como inibidores de proteìna cinase
FR2896246B1 (fr) 2006-01-13 2008-08-15 Sanofi Aventis Sa Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
EP1914234A1 (en) 2006-10-16 2008-04-23 GPC Biotech Inc. Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
FR2910813B1 (fr) * 2006-12-28 2009-02-06 Sanofi Aventis Sa Nouvelle utilisation therapeutique pour le traitement des leucemies
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
EP2352732B1 (en) * 2008-12-01 2013-02-20 Merck Patent GmbH 2,5-DIAMINO-SUBSTITUTED PYRIDO[4, 3-d]PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
ES2817448T3 (es) 2013-03-14 2021-04-07 Icahn School Med Mount Sinai Compuestos de pirimidina como inhibidores de quinasas
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
CN107286180B (zh) * 2016-04-11 2019-07-02 上海勋和医药科技有限公司 杂代吡啶并嘧啶酮衍生物作为cdk抑制剂及其应用
GB201709840D0 (en) 2017-06-20 2017-08-02 Inst Of Cancer Research: Royal Cancer Hospital Methods and medical uses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK281724B6 (sk) * 1994-11-14 2001-07-10 Warner-Lambert Company 6-arylpyrido[2,3-d]pyrimidíny, ich použitie a farmaceutické prostriedky na ich báze
IL115256A0 (en) * 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US5620981A (en) * 1995-05-03 1997-04-15 Warner-Lambert Company Pyrido [2,3-D]pyrimidines for inhibiting protein tyrosine kinase mediated cellular proliferation
KR20010043829A (ko) * 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 세포 증식 억제제로서의 비시클릭 피리미딘 및 비시클릭3,4-디히드로피리미딘

Also Published As

Publication number Publication date
EA200200643A1 (ru) 2002-12-26
OA12161A (en) 2006-05-08
PE20011066A1 (es) 2001-10-22
AP2002002586A0 (en) 2002-09-30
ZA200205879B (en) 2003-09-29
WO2001055147A1 (en) 2001-08-02
SV2002000294A (es) 2002-07-16
EP1254137A1 (en) 2002-11-06
YU50402A (sh) 2005-11-28
IS6443A (is) 2002-06-25
BG106850A (bg) 2003-02-28
GT200100016A (es) 2001-10-19
IL150545A0 (en) 2003-02-12
PL356802A1 (en) 2004-07-12
CA2397961C (en) 2008-08-26
NO20023527L (no) 2002-09-10
CA2397961A1 (en) 2001-08-02
CO5261549A1 (es) 2003-03-31
EE200200405A (et) 2003-12-15
MA26868A1 (fr) 2004-12-20
AU2542501A (en) 2001-08-07
DZ3266A1 (fr) 2001-08-02
AR030044A1 (es) 2003-08-13
JP2003523357A (ja) 2003-08-05
CR6706A (es) 2005-04-04
HN2001000013A (es) 2001-06-18
PA8510701A1 (es) 2002-12-11
NO20023527D0 (no) 2002-07-24
HUP0204141A2 (hu) 2003-04-28
JP4047010B2 (ja) 2008-02-13
HUP0204141A3 (en) 2005-03-29
SK10632002A3 (sk) 2003-06-03
KR20020065939A (ko) 2002-08-14
CZ20022475A3 (cs) 2003-03-12
BR0107751A (pt) 2002-11-12
TNSN01014A1 (fr) 2005-11-10
MXPA02007221A (es) 2002-11-29

Similar Documents

Publication Publication Date Title
CN1395578A (zh) 吡啶并[2,3－d]嘧啶－2,7－二胺激酶抑制剂
CN1138778C (zh) 用作细胞增殖抑制剂的二环嘧啶及二环3,4-二氢嘧啶化合物及用途
CN1083452C (zh) 抑制蛋白质酪氨酸激酶介导的细胞增殖的吡啶并[2,3－d]嘧啶
CN1085666C (zh) 用于抑制蛋白质酪氨酸激酶介导的细胞增殖的6－芳基吡啶并[2,3－d]嘧啶和1,5－二氮杂萘
CN1227249C (zh) 嘧啶化合物
CN1140269C (zh) 能够抑制表皮生长因子受体族酪氨酸激酶的双环化合物
HK1048992A1 (zh) 作为激酶抑制剂的蝶啶酮
CN1240688C (zh) 喹唑啉化合物
CN1860118A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN1422268A (zh) 5－烷基吡啶并[2,3－d]嘧啶酪氨酸激酶抑制剂
CN1128149C (zh) 6,9－二取代的2－[反－(4－氨基环己基)氨基]嘌呤
CN1551881A (zh) 新颖二氢喋啶酮,其制备方法及作为药物组合物的用途
CN1433417A (zh) 用于治疗神经变性疾病的吡啶并嘧啶酮衍生物
CN1675214A (zh) 具有抗增殖活性的嘧啶并化合物
CN101031560A (zh) 用作酪氨酸激酶抑制剂的环状二芳基脲
CN1655788A (zh) 治疗蛋白激酶依赖性疾病的1H－咪唑并[4,5－c]喹啉衍生物
CN101044137A (zh) 作为plk抑制剂的2,4－二（氨基苯基）嘧啶
CN1538847A (zh) 4-氨基-6-苯基-吡咯并[2,3-d]嘧啶衍生物
CN1960988A (zh) 作为蛋白激酶抑制剂的化合物和组合物
CN1711266A (zh) 具有抗增殖活性的嘧啶并化合物(ⅱ)
CN1094043A (zh) 喹唑啉衍生物
CN101039914A (zh) 作为激酶抑制剂的三氟甲基取代的苯甲酰胺化合物
CN1701073A (zh) 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5－a]嘧啶
CN1633419A (zh) Cdk抑制性嘧啶化合物、其制备方法以及作为药物的应用
CN1703414A (zh) 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1050364

Country of ref document: HK